The United States has extended its sprawling trade and technology control regime to cover the biotechnology sector as it is determined to “de-risk” from China.

As Hong Kong’s capital markets continue to have a strong year, one trend has been clear: The growing number of listings by Chinese biotech and biopharma companies.